Elevated Fcy receptor expression augments pro-inflammatory macrophage phagocytosis in systemic sclerosis and associated rheumatic diseases
This study highlights FcγR-expressing macrophages as drivers of phagocytosis and inflammatory responses in SSc. Dysregulated activation of these macrophages could lead to persistent inflammation and fibrosis in rheumatic diseases, highlighting new potential therapeutic approaches.
Authors
- Tracy Tabib (ORCID: https://orcid.org/0000-0003-4053-988X)
- Adrian Ciurea (ORCID: https://orcid.org/0000-0002-7870-7132)
- Przemysław Błyszczuk (ORCID: https://orcid.org/0000-0003-2521-3232)
- Raphael Micheroli (ORCID: https://orcid.org/0000-0002-8918-7304)
- Robert Lafyatis (ORCID: https://orcid.org/0000-0002-9398-5034)
- Michał Rudnik (ORCID: https://orcid.org/0000-0002-8716-6729)
- Suzana Jordan (ORCID: https://orcid.org/0000-0002-8114-8239)
- Oliver Distler (ORCID: https://orcid.org/0000-0002-0546-8310)
- Gabriela Kania (ORCID: https://orcid.org/0000-0003-3788-4594)
- Amela Hukara
- Kristina Bürki
- Gino A Bonazza
Institutions
- University of Pittsburgh (US)
- University of Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1093/rheumatology/keae688
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Acceleron
- Moderna
- Glenmark Pharmaceuticals
- Galderma
- Olga Mayenfisch Stiftung
- Genentech
- EMD Serono